Announcements

(Requests for announcements must be received at least 3 months before publication.)

NEW SCHEDULE FOR ANNUAL MEETINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH BEGINNING IN 1994

In May 1992 the Board of Directors of the American Association for Cancer Research voted to hold the AACR Annual Meeting separately from that of the American Society of Clinical Oncology (ASCO). The Board made this decision after careful consideration of the recommendations of the AACR’s Task Force on Clinical Investigations. It is felt that an independent annual meeting is essential to the vitally important goal of the AACR to provide more programs of relevance to clinical researchers and to have the AACR Annual Meeting serve as the primary forum for cancer research ranging from the bench to the clinic. The intent of scheduling the meetings consecutively has always been to facilitate interaction and scientific communication among clinical and laboratory scientists. However, the extraordinary recent growth in both meetings hampers that interaction. For a variety of reasons, investigators are unable to attend 7 consecutive days of scientific sessions. As a result, fewer than 20% of the AACR registrants also register for ASCO, and many of those who do register for both meetings attend only 1 day of the AACR meeting. The AACR feels that a separate Annual Meeting will enable more clinical researchers to attend the entire meeting of the AACR.

ASCO will continue to meet in mid-May. Starting in 1994, the AACR Annual Meeting will take place in late March or in April over dates that do not conflict with the FASEB meeting or the Easter and Passover holidays. The AACR meeting will be scheduled over 4 days. Regular scientific sessions will begin on Sunday morning and conclude on Wednesday afternoon to enable registrants to take advantage of airfare discounts requiring Saturday stay-overs.

The 1994 Annual Meeting will take place from Sunday, April 10 through Wednesday, April 13 at the Moscone Center in San Francisco, CA. The deadline for submission of abstracts will be October 25, 1993. Dates and locations have also been confirmed for the following years:

1994
March 19–22 Orlando, Florida
April 16–19 New York, NY
May 7–10 Seattle, WA
May 14–17 Los Angeles, CA
1995
March 19–22 Toronto, Ontario, Canada
April 21–24 Washington, DC
1996
April 19–22 San Antonio, TX
April 24–27 Seattle, WA
May 8–11 San Diego, CA
May 15–18 New York, NY
1997
March 17–20 Orlando, Florida
April 14–17 New Orleans, LA
May 12–15 San Francisco, CA
May 19–22 Chicago, IL
1998
March 16–19 New Orleans, LA
April 20–23 San Antonio, TX
May 11–14 Chicago, IL
May 18–21 Atlanta, GA
NEW PRIVILEGES AND RESPONSIBILITIES OF CORRESPONDING MEMBERSHIP

In a ballot distributed in Spring 1993, AACR members approved a number of amendments to the Association’s By-Laws. Several of these amendments affect the privileges and responsibilities of corresponding members. Corresponding members may now sponsor candidates for active, corresponding, and associate membership. All corresponding members, regardless of their year of election to the Association, are now required to pay dues. (Previously, dues payment had been voluntary for corresponding members elected before 1985.)

If qualified for emeritus membership, corresponding members may now transfer into this category and retain all of their previous membership privileges.

BROADENING OF ASSOCIATE MEMBERSHIP

Also approved in the recent By-Laws Ballot was an amendment broadening associate membership to qualified persons throughout the world. There will be no geographic restrictions. All graduate and medical students, postdoctoral fellows, and physicians-in-training who are following a course of study or who are working in a research program relevant to cancer investigations are now welcome to apply for this category of membership. One active or corresponding member of the Association in good standing must serve as a sponsor for the applicant. Annual dues for associate members are $30 for residents of the Americas, and $40 for those in other countries.

CALL FOR SUGGESTIONS FOR ASSOCIATION OFFICERS AND DIRECTORS

The Nominating Committee will prepare a slate of two AACR members for the office of President-Elect for 1994–95 and a slate of eight AACR members for four seats on the Board of Directors for 1994–97. The Committee intends to construct a slate which reflects the scientific and geographic diversity of the Association, and suggestions from members would be especially valuable in achieving this goal.

Members wishing to suggest candidates for President-Elect or for the Board should submit the name or names to the Association Office. A brief paragraph describing each candidate’s qualifications should accompany all suggestions; the Committee will obtain full dossiers for any nominee it wishes to consider more fully. Members’ suggestions should arrive in the AACR Office no later than November 5, 1993. Please note that, according to the Association’s By-Laws, any person who has previously been elected to a full term on the Board cannot stand for reelection until at least two years have passed since the conclusion of the term of office.

AACR SPECIAL CONFERENCES IN CANCER RESEARCH

A number of meetings are now being organized in the AACR’s new series of smaller scientific meetings. The topics, dates, locations, and program committees for these meetings are given on the following page. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to Meetings Mailing List, American Association for Cancer Research, Public Ledger Building, 620 Chestnut Street, Suite 816, Philadelphia, PA 19106-3483.

TUMOR IMMUNOLOGY: BASIC AND CLINICAL ASPECTS
November 7–11, 1993
Grove Park Inn, Asheville, NC
Chairperson
Ralph A. Reisfeld, San Diego, CA
Session Topics
Monoclonal Antibodies for Tumor Therapy
Genetically Engineered Antibodies
Gene Therapy of Cancer
Cytokines in Tumor Therapy
Tumor Antigens Recognized by T-Cells
Antibodies as Immunogens
Future of Cancer Immunotherapy

INTERACTIONS OF CANCER SUSCEPTIBILITY GENES AND ENVIRONMENTAL CARCINOGENS
(Join Meeting with the International Agency for Research on Cancer)
November 9–13, 1993
(Please note revised date)
International Agency for Research on Cancer,
Lyon, France
Chairpersons
Frederick P. Li, Boston, MA
Ruggero Montesano, Lyon, France
ANNOUNCEMENTS

Program Committee

AACR
J. Carl Barrett, Research Triangle Park, NC
Curtis C. Harris, Bethesda, MD
Carmen Sapienza, San Diego, CA
Lee W. Wattenberg, Minneapolis, MN
I. Bernard Weinstein, New York, NY

IARC
Kari K. Alitalo, Helsinki, Finland
Valerie Beral, Oxford, England
Dirk Bootsma, Rotterdam, the Netherlands
Bruce A. J. Ponder, Cambridge, England
Takashi Sugimura, Tokyo, Japan

Session Topics
Overview
Genetic Instability
Experimental Models of Genetic Susceptibility
DNA Damage and Repair
Mechanisms of Transgenerational Carcinogenesis
Human Cancers
Markers of Individual Exposure

CELL SIGNALING AND CANCER TREATMENT
(Joint Meeting with the British Association for Cancer Research and the European Organisation for Research and Treatment of Cancer [PAMM Group])
December 5–9, 1993
El San Juan Hotel, San Juan, PR

Chairpersons
Garth Powis, Tucson, AZ
Paul Workman, Glasgow, Scotland

Session Topics
Tyrosine Kinases and Inhibitors
Serine/Threonine Kinases and Inhibitors
GTP Binding Proteins
Domain Binding and Inhibition
Lipid Signaling
Modulation of Signaling in Combination Chemotherapy
Signaling and the Cell Cycle
Gene Targeting

RISK ASSESSMENT IN ENVIRONMENTAL CARCINOGENESIS
(Co-sponsored by the Environmental Mutagen Society)
January 17–22, 1994
(Banff Springs Hotel, Banff, Alberta, Canada)

Chairpersons
Philip C. Hanawalt, Stanford, CA
James A. Swenberg, Chapel Hill, NC

Program Committee
John Ashby, Macclesfield, England
William H. Farland, Washington, DC
Barry W. Glickman, Sydney, British Columbia, Canada
Carol J. Henry, Sacramento, CA
B. Singer, Berkeley, CA
Thomas R. Skopek, Research Triangle Park, NC
Roger W. Wiseman, Research Triangle Park, NC

Session Topics
Keynote Address: James A. Swenberg
Critical Events in Human Carcinogenesis
Molecular Epidemiology and Biomarkers of Exposure
Markers of Susceptibility and Genetic Predisposition
Mutational Spectra for Environmental Carcinogens
Endogenous Factors
Scientific Basis of Extrapolation
Biologically Based Risk Assessment and Public Policy

MOLECULAR GENETICS OF PROGRESSION AND METASTASIS
January 31–February 5, 1994
Big Sky Resort, Big Sky, MT

Chairperson
Lance A. Liotta, Bethesda, MD

Program Committee
Eric R. Fearon, New Haven, CT
Patricia S. Steeg, Bethesda, MD
William Stetler-Stevenson, Bethesda, MD
Dennis J. Slamon, Los Angeles, CA

Session Topics
Keynote Address: Marc E. Lippman
Colon Cancer
Melanoma
Breast and Ovarian Cancer
Prostate Cancer
Genomic Instability and Repair
Model Systems
Metastasis Suppression
Clinical Approaches to Cancer Progression

CANCER: PERTURBATIONS IN CELL CYCLE CONTROL AND GENOMIC INTEGRITY
(Co-sponsored by the National Cancer Institute of Canada)
February 19–24, 1994
BANFF SPRINGS HOTEL, BANFF, ALBERTA, CANADA

Chairpersons
Thea D. Tlsty, Chapel Hill, NC
Lawrence A. Loeb, Seattle, WA

Program Committee
Philippe Gros, Montreal, Quebec, Canada
Michael Smith, Vancouver, British Columbia, Canada

Session Topics
Keynote Address: Manfred Eigen
Modulators of Growth and Development
Tumor Suppressor Genes
Endogenous Sources of DNA Damage
Responses to DNA Damage
Controls of Genomic Integrity
Genetic Integrity and Carcinogenesis
Cell Cycle
Terminal Arrest

GROWTH FACTORS, DEVELOPMENT, AND CANCER
(Joint Meeting with the Friedrich Miescher-Institut)
March 5–11, 1994
Congress Center, Interlaken, Switzerland

Chairpersons
Harold L. Moses, Nashville, TN
Bernd Groner, Basel, Switzerland
Session Topics

**Special Lectures:**
- Harald zur Hausen
- Walter Gehring

**Positive and Negative Growth Factors and Their Receptors**
- Receptor-associated Kinases and Phosphatases
- Signal Transduction Including Targets for Therapy
- Transcription Factors and Homeobox Genes
- Tumor Suppressor Genes
- Cell-Cell Interactions
- Cell-Matrix Interactions and Proteases
- Targeted Therapy Including Immunotherapy

**TRANSCRIPTIONAL CONTROL OF CELL GROWTH & DIFFERENTIATION**

*October 16–20, 1994*

Chatham Bars Inn, Chatham (Cape Cod), MA

**Chairpersons**
- Eric N. Olson, Houston, TX
- Bruce M. Spiegelman, Boston, MA

**MODERN DEVELOPMENTS IN CANCER THERAPEUTICS**

*(Joint Meeting with Academia Sinica)*

*November 7–11, 1994*

Academia Sinica, Taipei, Taiwan, R.O.C.

**Chairperson**
- Yung-chi Cheng, New Haven, CT

**BASIC AND CLINICAL ASPECTS OF PROSTATE CANCER**

*December 8–13, 1994*

Marriott's Rancho Las Palmas Resort, Rancho Mirage (Palm Springs), CA

**Chairperson**
- Donald S. Coffey, Baltimore, MD

**CALENDAR OF EVENTS**

The Thirty-seventh Annual Clinical Conference: Advances in the Biology and Therapy of Colorectal Cancer, November 4–7, 1993, Hyatt Regency Houston, Houston, TX. Contact: Carol Harreld, Conference Services, Box 131, 1515 Holcombe Boulevard, Houston, TX 77030-4095. Telephone: (713) 792-2222.

Interdisciplinary Issues in Patient Education: Changing Roles and Delivery Models, November 6, 1993, R. Lee Clark Clinic Conference Center, M. D. Anderson Cancer Center, Houston, TX. Contact: Shirley Roy, Conference Services, Box 131, 1515 Holcombe Boulevard, Houston, TX 77030-4095. Telephone: (713) 792-2222.

Electrophoresis '93, November 7–10, 1993, Wild Dunes Resort and Conference Center, Charleston, SC. Contact: Mrs. Janet Cunningham, Electrophoresis Society, P.O. Box 279, Walkersville, MD 21793. Telephone: (301) 898-3772; FAX: (301) 898-5596.


Fifth Tokyo Symposium on Prostate Cancer, December 16–17, 1993, Keidanren Kaikan, Tokyo, Japan. Contact: Dr. James P. Karr, Office of Scientific Administration, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Telephone: (716) 845-2389; FAX: (716) 845-3545; or Dr. Kyoichi Imai, Department of Urology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma, 371, Japan. Telephone: 272-31-7221, ext. 3553; FAX: 272-35-5034.


Twelfth International Convocation on Immunology, Transfusion Immunology, and Medicine, May 14–18, 1994, Buffalo, NY. Credits: up to 24.5 hours CME. Contact: Dr. R. K. Cunningham, Director, 221 Sherman Hall, SUNY at Buffalo, 3435 Main Street, Buffalo, NY 14214-3078. Telephone: (716) 829-2848; FAX: (716) 829-2158.

Third International Workshop on Carcinoma-associated Mucins, August 7–11, 1994, Robinson College, Cambridge, UK. Contact: Dr. Joy Burchell or Mrs. Janice Ward, Imperial Cancer Research Fund, P.O. Box 123, 44 Lincoln's Inn Fields, London WC2A 3PX, UK. Telephone: 071-269-3456 or 071-269-3388; FAX: 071-269-3094.

The Second Denver Conference on Nutrition and Cancer, September 7–11, 1994, Denver, CO. Contact: Dr. Kedar N. Prasad, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262-0278.


**Erratum**

Several printer's errors occurred in the article by el Kouni et al., which appeared in the August 15, 1993 issue of Cancer Research, pp. 3687–3693. The equation on p. 3687 should have read:

\[
\text{Pyrimidine (deoxy)riboside} + P_i \leftrightarrow \text{Pyrimidine base} + (\text{deoxy)ribose-1-P}
\]

In addition, footnote b of Table 3 on p. 3690 should have read: "Apparent \( K_m \), \( \mu M \pm SE \) of estimation."